- Home
- JSPR vs ABOS Comparison
JSPR vs ABOS Comparison
Compare JSPR & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- ABOS
- Stock Information
- Founded
- JSPR 2018
- ABOS 1996
- Country
- JSPR United States
- ABOS United States
- Employees
- JSPR N/A
- ABOS N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- ABOS Health Care
- Exchange
- JSPR Nasdaq
- ABOS Nasdaq
- Market Cap
- JSPR 85.8M
- ABOS 76.9M
- IPO Year
- JSPR N/A
- ABOS 2021
- Fundamental
- Price
- JSPR $4.14
- ABOS $1.08
- Analyst Decision
- JSPR Strong Buy
- ABOS Strong Buy
- Analyst Count
- JSPR 10
- ABOS 3
- Target Price
- JSPR $62.50
- ABOS $7.33
- AVG Volume (30 Days)
- JSPR 216.1K
- ABOS 207.3K
- Earning Date
- JSPR 05-13-2025
- ABOS 03-27-2025
- Dividend Yield
- JSPR N/A
- ABOS N/A
- EPS Growth
- JSPR N/A
- ABOS N/A
- EPS
- JSPR N/A
- ABOS N/A
- Revenue
- JSPR N/A
- ABOS N/A
- Revenue This Year
- JSPR N/A
- ABOS N/A
- Revenue Next Year
- JSPR N/A
- ABOS N/A
- P/E Ratio
- JSPR N/A
- ABOS N/A
- Revenue Growth
- JSPR N/A
- ABOS N/A
- 52 Week Low
- JSPR $4.11
- ABOS $1.06
- 52 Week High
- JSPR $30.70
- ABOS $4.06
- Technical
- Relative Strength Index (RSI)
- JSPR 26.71
- ABOS 34.41
- Support Level
- JSPR $5.11
- ABOS $1.14
- Resistance Level
- JSPR $5.53
- ABOS $1.28
- Average True Range (ATR)
- JSPR 0.33
- ABOS 0.10
- MACD
- JSPR -0.01
- ABOS -0.00
- Stochastic Oscillator
- JSPR 1.87
- ABOS 3.57
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.